Court Gives Biopharma Patent Owners (A Little) Help In Inter Partes Review
In 9-4 en banc opinion, Federal Circuit finds PTAB decision that an inter partes review petition is not time-barred can be appealed; says Supreme Court left opening in Cuozzo ruling.
You may also be interested in...
En banc Federal Circuit says patent owners do not have to prove patentability of amended claims in inter partes review proceedings; judges issue five opinions in fractured decision.
High court says inconsistent decisions by Patent Trial and Appeal Board and district court are okay; House and Senate bills would eliminate the broad standard but opposition by tech community could doom passage.
The US FDA reports that the prescription drug user fee program met 27 of its 29 commitments by the end of FY 2021 and the biosimilar user fee program is on track to meet 16 of 27 of its performance enhancement goals.